Filed in archive
Drugs, Vaccines and Therapeutics
, Food and Agriculture
, Patents and Intellectual Property Rights
by ruth on January 12, 2006
The chemical company Bayer AG said Wednesday it has acquired Icon genetics AG, a biotech company working on methods for the development and use of engineered plants for producing pharmaceuticals and other high-value compounds.
The acquisition will strengthen Bayer's activities aimed at producing specific pharmaceutical substances in plants (plant-made pharmaceuticals, or PMPs). This technology utilizes the natural protein production processes in plants as a way of producing therapeutically active substances.
Icon Genetics AG has more than 40 patents that have been granted or applied for, including:
- RNA-Virus-Derived Plant Expression System
- Safe Production of a Product of Interest in Hybrid Seed
- Process of Producing a Plastid-Targeted Protein in Plant Cells
- Plant Transformation with in vivo Assembly of a Sequence of Interest
- Method of Protein Production in Plants
- Commercial Use of Arabidopsis for Production of Human and Animal Therapeutic and Diagnostic Proteins
Click here for a list of Icon Genetics' published patents.
Source: BayNews
Permalink: Bayer Buys Biotech Co. Icon Genetics
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/13691
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Bayer Buys Biotech Co. Icon Genetics:
|
Rating: 6.00 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
